894 related articles for article (PubMed ID: 32335286)
21. Phytocannabinoids as novel therapeutic agents in CNS disorders.
Hill AJ; Williams CM; Whalley BJ; Stephens GJ
Pharmacol Ther; 2012 Jan; 133(1):79-97. PubMed ID: 21924288
[TBL] [Abstract][Full Text] [Related]
22. Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment.
Asth L; Iglesias LP; De Oliveira AC; Moraes MFD; Moreira FA
Epilepsy Behav; 2021 Aug; 121(Pt B):106832. PubMed ID: 31839498
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder.
Zamberletti E; Rubino T; Parolaro D
Pharmacol Ther; 2021 Oct; 226():107878. PubMed ID: 33895189
[TBL] [Abstract][Full Text] [Related]
24. Cannabidivarin is anticonvulsant in mouse and rat.
Hill AJ; Mercier MS; Hill TD; Glyn SE; Jones NA; Yamasaki Y; Futamura T; Duncan M; Stott CG; Stephens GJ; Williams CM; Whalley BJ
Br J Pharmacol; 2012 Dec; 167(8):1629-42. PubMed ID: 22970845
[TBL] [Abstract][Full Text] [Related]
25. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.
Dos Santos RG; Hallak JEC; Crippa JAS
Adv Exp Med Biol; 2021; 1264():29-45. PubMed ID: 33332002
[TBL] [Abstract][Full Text] [Related]
26. Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects.
Morano A; Fanella M; Albini M; Cifelli P; Palma E; Giallonardo AT; Di Bonaventura C
Neuropsychiatr Dis Treat; 2020; 16():381-396. PubMed ID: 32103958
[TBL] [Abstract][Full Text] [Related]
27. Cannabis and Neuropsychiatric Disorders: An Updated Review.
Chayasirisobhon S
Acta Neurol Taiwan; 2019 Jun; 28(2)():27-39. PubMed ID: 31867704
[TBL] [Abstract][Full Text] [Related]
28. Current Cannabidiol Safety: A Review.
Singh C; Rao K; Yadav N; Vashist Y; Chugh P; Bansal N; Minocha N
Curr Drug Saf; 2023; 18(4):465-473. PubMed ID: 36056846
[TBL] [Abstract][Full Text] [Related]
29. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination.
Robaina Cabrera CL; Keir-Rudman S; Horniman N; Clarkson N; Page C
Pulm Pharmacol Ther; 2021 Aug; 69():102047. PubMed ID: 34082108
[TBL] [Abstract][Full Text] [Related]
30. Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines.
Arellano AL; Papaseit E; Romaguera A; Torrens M; Farré M
CNS Neurol Disord Drug Targets; 2017; 16(5):554-566. PubMed ID: 28412920
[TBL] [Abstract][Full Text] [Related]
31. Cannabis and its constituents for cancer: History, biogenesis, chemistry and pharmacological activities.
Lal S; Shekher A; Puneet ; Narula AS; Abrahamse H; Gupta SC
Pharmacol Res; 2021 Jan; 163():105302. PubMed ID: 33246167
[TBL] [Abstract][Full Text] [Related]
32.
Canseco-Alba A; Rodríguez-Manzo G
Rev Invest Clin; 2023; 75(3):105-128. PubMed ID: 37441766
[TBL] [Abstract][Full Text] [Related]
33. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
Qian Y; Gurley BJ; Markowitz JS
J Clin Psychopharmacol; 2019; 39(5):462-471. PubMed ID: 31433338
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and pharmacodynamics of cannabinoids.
Grotenhermen F
Clin Pharmacokinet; 2003; 42(4):327-60. PubMed ID: 12648025
[TBL] [Abstract][Full Text] [Related]
35. Medicinal Applications of Cannabinoids Extracted from Cannabis sativa (L.): A New Route in the Fight Against COVID-19?
Khalid S; Almalki FA; Hadda TB; Bader A; Abu-Izneid T; Berredjem M; Elsharkawy ER; Alqahtani AM
Curr Pharm Des; 2021; 27(13):1564-1578. PubMed ID: 33267756
[TBL] [Abstract][Full Text] [Related]
36. Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor.
Fischedick J; Van Der Kooy F; Verpoorte R
Chem Pharm Bull (Tokyo); 2010 Feb; 58(2):201-7. PubMed ID: 20118579
[TBL] [Abstract][Full Text] [Related]
37. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.
Bansal S; Maharao N; Paine MF; Unadkat JD
Drug Metab Dispos; 2020 Oct; 48(10):1008-1017. PubMed ID: 32587099
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of Action and Pharmacokinetics of Cannabis.
Chayasirisobhon S
Perm J; 2020 Dec; 25():1-3. PubMed ID: 33635755
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoids in treatment-resistant epilepsy: A review.
O'Connell BK; Gloss D; Devinsky O
Epilepsy Behav; 2017 May; 70(Pt B):341-348. PubMed ID: 28188044
[TBL] [Abstract][Full Text] [Related]
40. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.
Fasinu PS; Phillips S; ElSohly MA; Walker LA
Pharmacotherapy; 2016 Jul; 36(7):781-96. PubMed ID: 27285147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
